Emergent Biosolutions (EBS)

Jun 23, 2026, 8:00 AM EDT - 1 day ago

BioMendics Receives FDA Fast Track Designation for BM-3103 (TolaSure® Gel™) for Epidermolysis Bullosa Simplex

Jun 8, 2026, 2:00 PM EDT - 16 days ago

Emergent BioSolutions Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 8:02 AM EDT - 20 days ago

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Jun 3, 2026, 1:20 PM EDT - 21 days ago

Emergent BioSolutions Transcript: Jefferies Global Healthcare Conference 2026

2026-05-28T21:00:59.000Z - 27 days ago

Emergent BioSolutions awarded $64.5M HHS contract modification

May 28, 2026, 4:01 PM EDT - 27 days ago

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

May 20, 2026, 7:30 AM EDT - 5 weeks ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

2026-05-18T13:18:07.000Z - 5 weeks ago

Emergent BioSolutions receives Saudi approval for ACAM2000 vaccine

May 18, 2026, 8:59 AM EDT - 5 weeks ago

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

May 11, 2026, 7:53 AM EDT - 6 weeks ago

Hantavirus cases spark surge in pharma and biotech stocks — here's why

INO MRNA NVAX

Apr 30, 2026, 5:00 PM EDT - 7 weeks ago

Emergent BioSolutions Earnings Call Transcript: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 7 weeks ago

Emergent BioSolutions Earnings release: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 7 weeks ago

Emergent BioSolutions Slides: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 7 weeks ago

Emergent BioSolutions Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 7 weeks ago

Emergent BioSolutions Reports First Quarter 2026 Financial Results

2026-04-30T13:58:59.000Z - 7 weeks ago

Emergent BioSolutions receives Singapore regulatory approval for ACAM2000

Apr 30, 2026, 7:55 AM EDT - 7 weeks ago

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Apr 29, 2026, 9:00 AM EDT - 2 months ago

Emergent BioSolutions Transcript: AGM 2026

2026-04-29T12:30:52.000Z - 2 months ago

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

SABS

Apr 29, 2026, 7:35 AM EDT - 2 months ago

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

Apr 29, 2026, 6:53 AM EDT - 2 months ago

Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives

2026-04-28T12:59:14.000Z - 2 months ago

Emergent BioSolutions reports Imojev manufacturing pact with Substipharm

Apr 28, 2026, 8:01 AM EDT - 2 months ago

Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 16, 2026, 4:05 PM EDT - 2 months ago

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

Apr 16, 2026, 4:05 PM EDT - 2 months ago

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Emergent BioSolutions Proxy statement: Proxy filing

2026-04-09T20:31:33.000Z - 2 months ago

Emergent BioSolutions teams with British Columbia on Take-Home Naloxone Program

Apr 9, 2026, 4:25 PM EDT - 2 months ago

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

Apr 7, 2026, 8:05 AM EDT - 2 months ago

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

2026-03-25T20:26:40.000Z - 3 months ago

Emergent BioSolutions announces over $60M in government contract awards

Mar 25, 2026, 4:15 PM EDT - 3 months ago

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Mar 17, 2026, 12:49 PM EDT - 3 months ago

Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.

SIGA

2026-03-09T10:10:22.000Z - 3 months ago

Emergent BioSolutions price target lowered to $12 from $15 at H.C. Wainwright

2026-03-03T13:40:58.000Z - 4 months ago

Emergent BioSolutions appoints Fowler to board of directors

2026-03-03T13:27:16.000Z - 4 months ago

Emergent BioSolutions appoints Fowler to board of directors

Mar 3, 2026, 8:00 AM EST - 4 months ago

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

2026-02-26T22:51:12.000Z - 4 months ago

Emergent BioSolutions sees FY26 revenue $720M-$760M, consensus $809.4M

2026-02-26T22:45:39.000Z - 4 months ago

Emergent BioSolutions sees Q1 revenue $135M-$155M, consensus $275M

2026-02-26T22:40:37.000Z - 4 months ago

Emergent BioSolutions reports Q4 EPS (43c) vs. 5c last year

2026-02-26T22:36:31.000Z - 4 months ago

Emergent BioSolutions announces up to C$140M in Canadian contracts

2026-02-26T22:30:21.000Z - 4 months ago

Emergent BioSolutions authorizes $50M stock repurchase program

Feb 26, 2026, 5:00 PM EST - 4 months ago

Emergent BioSolutions Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 4 months ago

Emergent BioSolutions Annual report: Q4 2025

Feb 26, 2026, 5:00 PM EST - 4 months ago

Emergent BioSolutions Earnings release: Q4 2025

Feb 26, 2026, 5:00 PM EST - 4 months ago

Emergent BioSolutions Slides: Q4 2025

Feb 26, 2026, 4:05 PM EST - 4 months ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 4:01 PM EST - 4 months ago

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

Feb 26, 2026, 4:01 PM EST - 4 months ago

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

2026-02-12T23:05:22.000Z - 4 months ago

Emergent BioSolutions gets FDA approval of sNDA for Narcan

Feb 12, 2026, 6:00 PM EST - 4 months ago

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Feb 12, 2026, 9:02 AM EST - 4 months ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan 15, 2026, 1:08 PM EST - 5 months ago

NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

2026-01-15T16:50:51.000Z - 5 months ago

Former Emergent BioSolutions CEO sued by NY AG for insider trading

AZN

Jan 14, 2026, 8:15 PM EST - 5 months ago

Emergent BioSolutions Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 5 months ago

Emergent BioSolutions Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-14T13:05:41.000Z - 5 months ago

Emergent announces U.S. FDA approved sNDA for OTC NARCAN nasal spray

2026-01-12T12:47:27.000Z - 5 months ago

Emergent BioSolutions announces $100M paydown of term loan principal

Jan 12, 2026, 7:30 AM EST - 5 months ago

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Jan 8, 2026, 4:30 PM EST - 5 months ago

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Jan 8, 2026, 8:00 AM EST - 5 months ago

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Jan 7, 2026, 7:59 AM EST - 6 months ago

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 12, 2025, 8:30 AM EST - 6 months ago

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Nov 18, 2025, 8:00 AM EST - 7 months ago

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Nov 12, 2025, 4:01 PM EST - 8 months ago

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Oct 29, 2025, 5:00 PM EDT - 8 months ago

Emergent BioSolutions Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 8 months ago

Emergent BioSolutions Quarterly report: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 8 months ago

Emergent BioSolutions Earnings release: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 8 months ago

Emergent BioSolutions Slides: Q3 2025

Oct 29, 2025, 4:15 PM EDT - 8 months ago

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Oct 8, 2025, 7:45 AM EDT - 9 months ago

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Sep 24, 2025, 4:05 PM EDT - 9 months ago

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Sep 19, 2025, 8:34 AM EDT - 9 months ago

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Sep 15, 2025, 8:35 AM EDT - 10 months ago

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Sep 9, 2025, 7:30 AM EDT - 10 months ago

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Sep 4, 2025, 3:00 PM EDT - 10 months ago

Emergent BioSolutions Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 7:40 AM EDT - 10 months ago

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Aug 29, 2025, 8:05 AM EDT - 10 months ago

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Aug 21, 2025, 8:45 AM EDT - 10 months ago

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Emergent BioSolutions Registration statement: Registration Filing

Aug 6, 2025, 5:00 PM EDT - 11 months ago

Emergent BioSolutions Earnings Call Transcript: Q2 2025

Aug 6, 2025, 5:00 PM EDT - 11 months ago

Emergent BioSolutions Quarterly report: Q2 2025

Aug 6, 2025, 5:00 PM EDT - 11 months ago

Emergent BioSolutions Earnings release: Q2 2025

Aug 6, 2025, 5:00 PM EDT - 11 months ago

Emergent BioSolutions Slides: Q2 2025

Aug 6, 2025, 4:15 PM EDT - 11 months ago

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Jul 28, 2025, 8:50 AM EDT - 11 months ago

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

Jul 28, 2025, 8:50 AM EDT - 11 months ago

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Jul 15, 2025, 7:30 AM EDT - 1 year ago

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 8, 2025, 4:45 PM EDT - 1 year ago

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Jul 2, 2025, 4:05 PM EDT - 1 year ago

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Jun 23, 2025, 8:05 AM EDT - 1 year ago

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Jun 20, 2025, 8:13 AM EDT - 1 year ago

Emergent BioSolutions Announces Addition to Russell 3000® Index